Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Infantile hemangioma (IH) is the most common benign vascular tumor in pediatric population.
Oral propranolol is the treatment of choice for complicated hemangiomas. Topical timolol, a
non-selective beta-blocker, is an emerging treatment which has been reported to be effective
and safe for the treatment of IH, especially for superficial hemangiomas. Investigators
hypothesize that treatment with topical timolol in the first two months of life, before the
proliferative phase or in early proliferative phase, may prevent from further growing and the
need to treat with oral propranolol.
Phase:
Phase 2
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau